By Billy Candra 
A novel treatment protocol developed by researchers at Cambridge has demonstrated a remarkable improvement in survival rates for patients battling aggressive, inherited forms of breast cancer. In a pivotal clinical trial, 100% of participants treated with a specific sequence of chemotherapy followed by a targeted cancer drug before surgery survived the critical three-year period post-operation, marking a significant leap forward in oncology. This discovery, detailed in a new publication in Nature Communications, heralds a potential paradigm shift in the management of early-stage breast cancer associated with inherited BRCA1 and BRCA2 gene mutations, offering renewed hope to a patient population historically facing formidable challenges.
The Partner Trial: A New Frontier in Breast Cancer Treatment
The "Partner" trial, spearheaded by Addenbrooke’s Hospital, part of Cambridge University Hospitals (CUH) NHS Foundation Trust, and the University of Cambridge, introduced a revolutionary two-pronged approach. This involved the strategic addition of olaparib, a targeted cancer drug, alongside chemotherapy administered pre-surgery (neoadjuvant therapy). Crucially, the trial also illuminated the profound benefits of meticulously timing these treatments, specifically incorporating a 48-hour "gap" between the chemotherapy and the commencement of olaparib. This innovative regimen deviates significantly from current standard practices, which typically focus on shrinking tumours with chemotherapy and sometimes immunotherapy before surgical removal, followed by an extended course of targeted therapy if needed.
The first three years following surgery are universally recognized as a high-risk window for relapse or mortality in breast cancer patients. The Partner trial’s unprecedented 100% survival rate within this critical period for the intervention arm stands in stark contrast to the control group, where the survival rate was 88% after three years. Among the 39 patients who received the experimental combination, only one experienced a relapse three years post-surgery, with all patients surviving. Conversely, in the control arm of 45 patients who received chemotherapy alone, nine relapsed, and tragically, six of those patients died. These statistics underscore the profound impact of the new treatment strategy, offering a compelling case for its broader adoption.
Understanding BRCA Mutations and Their Clinical Significance
Breast cancers linked to faulty copies of the BRCA1 and BRCA2 genes are notoriously aggressive and complex to treat. These genes play a vital role in DNA repair, acting as tumour suppressors. When mutated, their ability to repair damaged DNA is compromised, leading to an increased risk of cellular mutations that can drive cancer development. While BRCA mutations are responsible for only 5-10% of all breast cancers, they account for a disproportionately higher percentage of hereditary breast cancers and are often associated with more aggressive subtypes, such as triple-negative breast cancer, which lacks receptors for oestrogen, progesterone, and HER2, making it harder to target with conventional hormone or HER2-specific therapies.
Public awareness of BRCA mutations surged in 2013 when actress Angelina Jolie, a carrier of a BRCA1 mutation, publicly announced her preventative double mastectomy. This "Angelina Jolie effect" significantly increased discussions around genetic testing and risk-reducing surgeries, highlighting the personal stakes involved in inherited cancer predispositions and underscoring the urgent need for more effective treatments for those who develop cancer despite preventative measures. The Partner trial directly addresses this unmet clinical need, offering a lifeline to individuals diagnosed with these challenging forms of the disease.
The Role of Olaparib and the Strategic 48-Hour Gap
Olaparib, a targeted cancer drug, is an oral poly (ADP-ribose) polymerase (PARP) inhibitor. PARP enzymes are crucial for repairing single-strand DNA breaks. In cells with compromised DNA repair pathways due such as those with BRCA mutations, inhibiting PARP leads to a buildup of unrepaired DNA damage, ultimately triggering cancer cell death. This concept, known as "synthetic lethality," exploits the inherent weakness of BRCA-deficient cancer cells, making PARP inhibitors particularly effective in this specific patient population. Olaparib is already available on the NHS for certain indications, including some ovarian and breast cancers, typically administered post-surgery. The innovation of the Partner trial lies not just in its use, but in its strategic placement within the treatment timeline and the introduction of the carefully timed pause.
The results indicating superior outcomes with a 48-hour gap between chemotherapy and olaparib are particularly intriguing. Professor Jean Abraham, a consultant at Addenbrooke’s and the trial lead, along with Mark O’Connor, chief scientist in Early Oncology R&D at AstraZeneca, hypothesized that this brief interlude allows a patient’s healthy bone marrow cells to recover from the cytotoxic effects of chemotherapy. Meanwhile, the rapidly dividing tumour cells, already weakened by chemotherapy and inherently deficient in DNA repair due to BRCA mutations, remain highly susceptible to the subsequent targeted attack by olaparib. This strategic timing potentially minimizes collateral damage to healthy tissues while maximizing the therapeutic impact on the cancer, leading to both improved efficacy and potentially a less toxic treatment experience.
A Patient’s Journey: Hope and Renewal
The human impact of these scientific breakthroughs is best encapsulated by patient stories. Jackie Van Bochoven, 59, from South Cambridgeshire, was diagnosed in February 2019 with an aggressive, albeit small, tumour. Her initial reaction was one of profound shock and fear, intensified by her family history of breast cancer. "When I had the diagnosis, I was completely shocked and numb, I thought about my children, and my mum and sister who were diagnosed with breast cancer. I was pretty worried," she recounted.
Participating in the Partner trial offered Jackie a pathway to hope. Six years later, she stands as a testament to the treatment’s success. "Six years on, I’m well and cancer free. I’m back at work, enjoying life and spending time with my family. When you’ve had cancer, I think you look at life differently and every day is a bonus," she shared, her words echoing the profound gratitude and renewed perspective that comes with overcoming such a formidable illness. Her experience provides a powerful, tangible example of the trial’s potential to transform lives.
Broader Implications and Future Directions
The significance of the Partner trial extends beyond breast cancer. The findings hold immense potential for application to other cancers driven by faulty BRCA genes, including certain ovarian, prostate, and pancreatic cancers. This suggests that the strategic combination and timing of chemotherapy with PARP inhibitors could become a foundational element in a new class of treatments for a range of hereditary cancers.
Furthermore, the trial offers promising economic benefits for the NHS. Currently, patients offered olaparib typically take the drug post-surgery for a duration of 12 months. In contrast, patients on the Partner trial received the tablets pre-surgery for a significantly shorter period of just 12 weeks. This reduced duration of targeted therapy not only potentially lessens the burden of treatment for patients but also represents a substantial cost-saving opportunity for healthcare systems without compromising, and indeed, improving efficacy. This financial aspect could accelerate its adoption, especially in resource-constrained healthcare environments.
Professor Jean Abraham expressed profound enthusiasm for the results: "It is rare to have a 100% survival rate in a study like this and for these aggressive types of cancer. We’re incredibly excited about the potential of this new approach, as it’s crucial that we find a way to treat and hopefully cure patients who are diagnosed with BRCA1 and BRCA2 related cancers." Her colleague, Mark O’Connor, echoed this sentiment, emphasizing the trial’s role in "highlighting the importance of detecting and treating cancer early, and the value of innovative science in informing clinical trial design." He cautiously added that while the findings need validation in a larger study, "they’re incredibly exciting, and have the potential to transform outcomes for patient populations who have unmet clinical need."
The Power of Collaboration: A Vision for Cambridge Cancer Research Hospital
The success of the Partner trial is a vivid illustration of the power of collaborative research, bringing together clinical expertise, academia, and industry. The trial was sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, funded by Cancer Research UK and AstraZeneca, and further supported by the NIHR Cambridge Biomedical Research Centre, the Cancer Research UK Cambridge Centre, and Addenbrooke’s Charitable Trust (ACT). This multi-faceted support system underscores the collective commitment to advancing cancer care.
This collaborative spirit aligns perfectly with the vision for the Cambridge Cancer Research Hospital, a specialist facility slated for construction on the Cambridge Biomedical Campus, Europe’s leading life sciences hub. This new hospital aims to consolidate clinical expertise from Addenbrooke’s with world-class scientists from the University of Cambridge, the Cancer Research UK Cambridge Centre, and industry partners. The goal is to foster an environment where groundbreaking research directly translates into new diagnostics and treatments, enabling the earliest detection of cancer and the delivery of highly personalized, precision medicine tailored to individual patient needs.
Michelle Mitchell, Chief Executive of Cancer Research UK, highlighted the strategic importance of maximizing existing treatments. "One of the best ways that we can beat cancer sooner is by making more effective use of treatments that are already available to us," she stated. "While this research is still in its infancy, it is an exciting discovery that adding olaparib at a carefully-timed stage of treatment can potentially give patients with this specific type of breast cancer more time with their loved ones." She also noted the necessity for further studies to confirm safety and efficacy for NHS integration.
Looking Ahead: Next Steps in Validation and Implementation
Professor Abraham and her team are now diligently planning the next phase of research. This will involve a larger-scale study designed to replicate these compelling results and definitively confirm that the Partner approach offers not only superior efficacy but also a less toxic and more cost-effective treatment option compared to current standard care. Such comprehensive validation is crucial for securing regulatory approval and widespread adoption within national healthcare systems. The journey from groundbreaking discovery to established clinical practice is often long and arduous, but the early signs from the Partner trial are exceptionally promising, paving the way for a transformative shift in how aggressive inherited breast cancers are treated. The prospect of offering a "cure" for these challenging cancers, as Professor Abraham optimistically suggests, represents a monumental achievement that could redefine the landscape of oncology for countless patients worldwide.